Equities

Xbrane Biopharma AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Xbrane Biopharma AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)6.21
  • Today's Change-0.145 / -2.28%
  • Shares traded43.27k
  • 1 Year change-68.38%
  • Beta1.2486
Data delayed at least 15 minutes, as of Mar 02 2026 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.

  • Revenue in SEK (TTM)152.35m
  • Net income in SEK-46.17m
  • Incorporated2008
  • Employees29.00
  • Location
    Xbrane Biopharma ABRetzius Vag 8SOLNA 171 65SwedenSWE
  • Phone+46 855905600
  • Websitehttps://xbrane.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Opsy Holding AB6.69m-7.86m81.26m7.00--52.66--12.14-8.55-8.550.7050.12150.8126--9.41955,857.10-95.38-129.63-199.92-161.05144.70---117.38-2,431.63---69.760.435------62.94--43.17--
Biosergen AB0.00-40.82m90.17m1.00---------17.68-17.680.00---------------------------------------112.64------
Biovica International AB9.86m-76.47m99.90m24.00--0.8488--10.13-0.6375-0.63750.06840.42410.079912.714.46365,333.30-61.92-58.22-70.41-66.49-171.53-462.09-775.22-1,804.168.11--0.0239--18.2338.8329.80---47.26--
Coegin Pharma AB79.00k-20.50m102.00m3.00--21.50--1,291.11-0.824-0.8240.00320.19070.0039--2.16---101.52-113.82-136.64-160.62-974.68---25,945.57-170,432.90---681.70--------13.81------
Exact Therapeutics AS0.00-68.54m102.09m12.00--1.59-----1.40-1.400.001.070.00----0.00-108.82-43.50-168.39-50.76-----------20.180.0052-------8.27--1.47--
Alzinova AB205.00k-26.88m102.49m5.00--0.501--499.94-0.2846-0.28460.00221.230.0015--0.325441,000.00-19.42-12.21-20.69-12.85-5,834.15---13,114.15-21,390.81---1,794.800.0062---88.89---24.71--19.48--
Alligator Bioscience AB514.00k-51.35m102.73m13.00--1.23--199.87-1.09-1.090.00740.15660.0048--1.98---47.78-101.41---222.85-----9,990.27-526.56----0.8354---99.11-34.7778.05--70.30--
Annexin Pharmaceuticals AB (publ)0.00-36.89m103.06m4.00--4.13-----5.98-5.980.003.530.00----0.00-150.00-137.53-190.93-169.50------------0.00------26.58------
Glycorex Transplantation AB (publ)38.84m-7.72m106.20m20.00--3.2167.432.73-0.0983-0.09830.49520.4380.76851.356.371,942,200.00-15.27-17.65-20.85-21.4582.8485.42-19.87-41.501.35-16.240.1682--10.487.5529.44---37.57--
Abera Bioscience AB0.00-10.45m112.71m5.00--5.84-----0.5692-0.56920.001.040.00-------49.58-63.36-74.82-81.05---------------------850.27------
Xbrane Biopharma AB152.35m-46.17m127.86m29.00--0.228--0.8392-106.731,665.7629.0727.210.20130.284712.915,253,586.00-6.10-25.02-10.00-43.0458.77---30.30-144.313.43-1.800.0942--2.87--67.33--105.02--
SoftOx Solutions AS12.90m-2.85m135.01m5.00--1.31176.6010.47-0.001-0.0010.00650.04450.123--30.132,717,798.00-2.72-50.91-3.22-67.07-----22.07-644.921.16-3.920.1212--13.3814.06-8.86------
Active Biotech AB publ0.00-37.30m137.34m5.00--2.47-----0.0236-0.02360.000.02110.00----0.00-65.79-93.70-82.91-119.51------------0.0018------5.33------
NextCell Pharma AB10.94m-35.14m150.38m24.00--2.27--13.75-0.4414-0.44140.1330.5960.138451.234.68---44.48-34.95-49.25-37.53-155.37-266.34-321.31-427.089.92------2.5625.1316.25--36.88--
ViroGates A/S7.20m-17.69m157.07m7.00--32.33--21.82-1.63-1.630.66090.36650.35680.97774.41504,300.00-87.63-54.92-131.36-63.1547.3372.98-245.63-215.481.58-16.130.6277---12.276.45-18.59------
SenzaGen AB57.97m-15.95m174.24m37.00--2.03--3.01-0.5405-0.54051.962.630.50847.263.57---13.98-17.45-17.59-21.8964.8066.40-27.51-45.192.17--0.1953--0.483648.76-8.14--169.98--
Data as of Mar 02 2026. Currency figures normalised to Xbrane Biopharma AB's reporting currency: Swedish Krona SEK

Institutional shareholders

2.38%Per cent of shares held by top holders
HolderShares% Held
Handelsbanken Fonder ABas of 31 Jan 2026307.77k1.49%
SEB Funds ABas of 30 Jan 202693.88k0.46%
Storebrand Asset Management ASas of 31 Jan 202684.62k0.41%
FCG Fonder ABas of 31 Mar 20252.12k0.01%
Skandia Investment Management ABas of 28 Nov 2025709.000.00%
Danske Bank A/S (Investment Management)as of 31 Jan 2026523.000.00%
Dimensional Fund Advisors LPas of 30 Nov 20250.000.00%
More ▼
Data from 30 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.